Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.96 USD
Change Today +0.18 / 1.67%
Volume 558.2K
AFFX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFFX) Key Developments

Affymetrix Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Raises Financial Guidance for the Full Year of 2015

Affymetrix Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $88,966,000 against $85,432,000 a year ago. Profit from operations was $8,526,000 against loss from operations of $304,000 a year ago. Profit before income taxes was $7,330,000 against loss before income taxes of $509,000 a year ago. Net profit was $7,006,000 or $0.08 diluted per share against net loss of $911,000 or $0.01 basic and diluted per share a year ago. Non-GAAP net income was $10,454,000 or $0.12 diluted per share against $5,157,000 or $0.07 basic and diluted per share a year ago. EBITDA was $14,138,000 compared to $10,676,000 for the same period a year ago. Adjusted EBITDA was $17,134,000 compared to $13,864,000 for the same period a year ago. In the second quarter, the company generated solid cash flow, around about $10 million from operating activities. For the six months, the company reported total revenue of $177,684,000 against $168,403,000 a year ago. Profit from operations was $15,810,000 against loss from operations of $9,045,000 a year ago. Profit before income taxes was $12,459,000 against loss before income taxes of $10,711,000 a year ago. Net profit was $11,392,000 or $0.14 diluted per share against $11,385,000 or $0.16 basic and diluted per share a year ago. Non-GAAP net income was $18,338,000 or $0.21 diluted per share against $7,061,000 or $0.10 basic and diluted per share a year ago. EBITDA was $26,283,000 compared to $13,813,000 for the same period a year ago. Adjusted EBITDA was $34,265,000 compared to $26,780,000 for the same period a year ago. The company reiterates guidance for full year revenue growth in the mid-single digit range on a constant currency basis, increased gross margin, and raising adjusted EBITDA guidance from a range of 16-18% to 17-19% for 2015. The company increase 2015 full year guidance for non-GAAP gross margin from 61% to 63%.

Cytox Partners with Affymetrix to Collaborate on Developing and Commercializing Blood-Based Genetic Assay for Research in Diagnosis and Prognosis of Alzheimer's Disease and Mild Cognitive Impairment

Cytox Ltd. and Affymetrix Inc. have formed a strategic partnership to collaborate on developing and commercializing a blood-based genetic assay for research in diagnosis and prognosis of Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). The transaction will allow Affymetrix to extend its offering into the Alzheimer's disease (AD) and dementia research market with a new application.

Affymetrix, Inc., BioRealm, LLC, and RUCDR Infinite Biologics Announce Broad Strategic Alliance

Affymetrix Inc., BioRealm, LLC, and RUCDR Infinite Biologics announced a broad strategic alliance. This alliance will leverage BioRealm's SmokeScreen® platform to genotype the National Institute on Drug Abuse (NIDA) biorepository of more than 50,000 samples, collected from human subjects studied in NIDA-funded research. NIDA preserves these samples in a biorepository at RUCDR Infinite Biologics, on the campus of Rutgers University. The biorepository is maintained by RUCDR Infinite Biologics and in part through collaboration with the BioProcessing Solutions Alliance which was created by RUDCR Infinite Biologics and BioStorage Technologies. Once the genetic information contained in these samples is made available to researchers, it will be extremely valuable for studying the link between genetic variations and addiction. Detailed genetic information might, for example, be used by researchers exploring how genetics influences patients’ individual responses to treatment approaches. To date, the genetic information contained in these samples has been focused on specific targets and not collectively analyzed. This strategic alliance makes it possible, for the first time ever, to cost-efficiently analyze this valuable information. The genetic information will be obtained by using BioRealm’s SmokeScreen® array, developed in conjunction with NIDA’s Genetics Consortium and Affymetrix. SmokeScreen® array is a genome-wide array with research-driven focus on more than 1,000 addiction-related genes.

Affymetrix Inc. to Report Q2, 2015 Results on Jul 29, 2015

Affymetrix Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 29, 2015

Affymetrix Inc., Q2 2015 Earnings Call, Jul 29, 2015

Affymetrix Inc., Q2 2015 Earnings Call, Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFFX:US $10.96 USD +0.18

AFFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $20.03 USD +0.29
Foundation Medicine Inc $20.30 USD -2.00
Luminex Corp $17.23 USD +0.18
Sequenom Inc $2.82 USD +0.02
Takara Bio Inc ¥1,347 JPY +32.00
View Industry Companies
 

Industry Analysis

AFFX

Industry Average

Valuation AFFX Industry Range
Price/Earnings 49.7x
Price/Sales 2.4x
Price/Book 2.6x
Price/Cash Flow 46.2x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.